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Abstract
Objective—To investigate the HPV testing recommendations of US physicians who perform 
cervical cancer screening.
Methods—Data from the 2015 DocStyles survey of U.S. health care providers were analyzed 
using multivariate logistic regression to identify provider characteristics associated with routine 
recommendation of primary HPV testing for average-risk, asymptomatic women ≥30 years old. 
The analysis was limited to primary care physicians and obstetrician-gynecologists who performed 
cervical cancer screening (N = 843).
Results—Primary HPV testing for average-risk, asymptomatic women ≥30 years old was 
recommended by 40.8% of physicians who performed cervical cancer screening, and 90.1% of 
these providers recommended primary HPV testing for women of all ages. The screening intervals 
most commonly recommended for primary HPV testing with average-risk, asymptomatic women 
≥30 years old were every 3 years (35.5%) and annually (30.2%). Physicians who reported that 
patient HPV vaccination status influenced their cervical cancer screening practices were almost 
four times more likely to recommend primary HPV testing for average-risk, asymptomatic women 
≥30 years old than other providers (Adj OR = 3.96, 95% CI = 2.82–5.57).
Conclusion—Many US physicians recommended primary HPV testing for women of all ages, 
contrary to guidelines which limit this screening approach to women ≥25 years old. The 
association between provider recommendation of primary HPV testing and patient HPV 
vaccination status may be due to anticipated reductions in the most oncogenic HPV types among 
vaccinated women.
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1. Introduction
The US Food and Drug Administration approved a human papillomavirus (HPV) test that 
can distinguish vaccine HPV types from other oncogenic HPV types for primary cervical 
cancer screening in 2014 (Nelson, 2014). In 2015, the American Society for Colposcopy and 
Cervical Pathology (ASCCP) and the Society of Gynecology Oncology (SGO) issued 
clinical guidance recommending primary HPV testing every 3 years for women ≥25 years 
old as one of several screening strategies (Huh et al., 2015), and the American College of 
Obstetricians and Gynecologists (ACOG) recommended this screening strategy in 2016 
(American College of Obstetricians and Gynecologists, 2016). However, primary screening 
with the HPV test has not been recommended by the American Cancer Society (ACS) 
(Saslow et al., 2012) and the US Preventive Services Task Force (USPSTF) (US Preventive 
Services Task Force, 2012), which endorse two screening options: 1) Papanicolaou (Pap) 
testing every 3 years for women 21–65 years old and 2) Pap testing every 3 years for women 
21–29 years old followed by testing with both the Pap test and the HPV test (co-testing) 
administered every 5 years for women 30–65 years old.
This study investigated US physicians’ HPV testing recommendations in 2015 to assess 
uptake of this newer screening strategy.
2. Methods
The 2015 DocStyles survey was administered online in June by Porter Novelli (Washington 
D.C.). Participants were recruited from SERMO’s Global Medical Panel® (> 330,000 US 
health professionals, verified through telephone confirmation at their place of work). 
Participants included physicians practicing in a variety of settings (solo practices, group 
practices, managed care organizations, etc.), but were limited to providers who worked in 
the United States, actively saw patients, and had practiced for at least 3 years. The survey 
included a variety of provider groups, but the analyses reported here were limited to primary 
care physicians (internists and family practitioners) and obstetrician-gynecologists.
An invitation to participate in the survey was emailed to randomly-selected panel members
—1569 (1122 primary care physicians and 347 obstetrician-gynecologists). Of this sample, 
1250 (79.7%) comprised of 1000 primary care physicians and 250 obstetrician-
gynecologists completed the survey. Quota sampling (Cumming, 1990) was used to ensure 
adequate representation of all provider groups surveyed; the quotas were filled: 1000 
primary care physicians and 250 obstetrician-gynecologists. Fifty-eight (3.7% of sample, 44 
primary care physicians and 14 obstetrician-gynecologists) were terminated based on 
screening questions; 30 (1.9% of sample, 23 primary care physicians and 7 obstetrician-
gynecologists) did not complete the survey; 24 (1.5% of sample, 10 primary care physicians 
and 14 obstetrician-gynecologists) were terminated due to filled quotas; 107 (6.8%, 45 
primary care physicians and 62 obstetrician-gynecologists) did not respond to the invitation 
to participate in the survey or responded after the survey closed. Of the 1250 providers who 
completed the survey, 407 (399 primary care physicians and 8 obstetrician-gynecologists) 
were excluded because they reported that cervical cancer screening was not within the scope 
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of their practice or performed no cervical cancer screening within a typical month, resulting 
in a sample of 843 (601 primary care physicians and 242 obstetrician-gynecologists).
Respondents were not required to participate and could exit the survey at any time. 
Respondents were paid $35–$80 depending on specialty. The survey questions analyzed in 
the present study were developed by multi-disciplinary team of researchers from CDC and 
Porter Novelli. The study complied with the ICC/ESOMAR International Code for ethical 
research (ESOMAR, 2008) and was not subject to CDC IRB review as it involved secondary 
data analysis, and no individual identifiers were included in the dataset received by 
investigators.
In addition to providing demographic characteristics and practice information, respondents 
rated the influence of four factors on their cervical cancer screening practices: “clinical 
experience,” “patient preference,” “patient HPV vaccination status,” and “practice 
guidelines.” Responses provided were “not at all,” “slightly,” “somewhat,” and “very much” 
and were dichotomized into “does not influence” (“not at all” and “slightly”) and 
“influences” (“somewhat” and “very much”).
Respondents were also asked which cervical cancer screening options and intervals they 
routinely recommended to average-risk, asymptomatic women in three age groups: “24 
years and younger,” “25–29 years,” and “30 years and older.” Screening options listed for 
each age group of patients were “co-testing (Pap test in combination with HPV test),” “Pap 
test alone,” and “HPV test alone” (screening options were listed in this order together in a 
single block beneath each age-specific scenario). Responses provided were “do not 
recommend,” “annual,” “every 2 years,” “every 3 years,” “every 4 years,” “every 5 years,” 
and “other.” A single response was accepted for each screening option. Routine 
recommendation of HPV test alone was dichotomized into “do not recommend” and 
“recommend” (all other responses).
Pairwise Pearson Chi-square tests were performed to test the associations between the 
routine recommendation of primary HPV testing for average-risk, asymptomatic women ≥30 
years old and provider characteristics. Variables significantly associated (p < 0.05) with 
routine recommendation of primary HPV testing in the bivariate analyses were included in a 
forward stepwise multivariate logistic regression model predicting routine recommendation 
of primary HPV testing for average-risk, asymptomatic women ≥30 years old. The data were 
analyzed in 2016 using IBM SPSS Statistics 21.0.
3. Results
The most common influences on cervical cancer screening practices were practice 
guidelines (89.1%) and clinical experience (73.1%) (Table 1). For average-risk, 
asymptomatic women, the Pap test alone was the most popular screening recommendation 
for women < 25 years old (81.4%) and 25–29 years old (80.9%), and co-testing was 
recommended most often for women ≥30 years old (94.4%).
Primary HPV testing for average-risk, asymptomatic women ≥30 years old was 
recommended by 40.8% of physicians who performed cervical cancer screening. Among 
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these, 90.1% (36.8% of sample) recommended primary HPV testing for women of all ages 
(< 25 years old, 25–29 years old, and ≥30 years old). The screening intervals most 
commonly recommended for primary HPV testing for average-risk, asymptomatic women 
≥30 years old were every 3 years (35.5%) and annually (30.2%) (Fig. 1).
In the bivariate analyses, routine recommendation of primary HPV testing to average-risk, 
asymptomatic women ≥30 years old was more likely among internists, male providers, 
Asian providers, Hispanic providers, and providers who reported that their cervical cancer 
screening practices were influenced by patient preference or patient HPV vaccination status 
(Table 2). And, routine recommendation of primary HPV testing to average-risk, 
asymptomatic women ≥30 years old was less likely among providers who screened ≥45 
women for cervical cancer during a typical month, and providers who reported that practice 
guidelines influenced their cervical cancer screening practices. Years in practice, number of 
providers in practice, teaching hospital privileges, region, financial status of majority of 
patients treated, and one of the four factors influencing cervical cancer screening practices 
(clinical experience) were not associated with routine recommendation of primary HPV 
testing to average-risk, asymptomatic women ≥30 years old.
In the adjusted logistic regression model, physicians who reported that patient HPV 
vaccination status influenced their cervical cancer screening practices were almost four 
times more likely to routinely recommend primary HPV testing to average-risk, 
asymptomatic women ≥30 years old than other providers (Table 3). The observed 
associations with specialty, gender, race, ethnicity, and practice guidelines influencing 
cervical cancer screening practices also persisted in the adjusted model.
4. Discussion
The Pap test alone and co-testing remained the dominant cervical cancer screening 
modalities recommended by providers, but > 40% recommended primary HPV testing. This 
result was surprising given the recency of SGO/ASCCP (Huh et al., 2015) and ACOG 
(American College of Obstetricians and Gynecologists, 2016) recommendations for primary 
HPV testing, and the absence of guidelines on this screening strategy from ACS (Saslow et 
al., 2012) and USPSTF (US Preventive Services Task Force, 2012). However, prior national 
surveys of US providers found widespread agreement that the HPV test administered alone 
is an effective screening modality in 2012 (79.5%–91.8%, depending on provider specialty) 
and 2009 (75.3%–86.1%) (Cooper and Saraiya, 2015).
Provider HPV testing recommendations were not consistent with available guidance. Most 
providers who endorsed primary HPV testing in our survey recommended it for women of 
all ages, despite guidance to limit this strategy to women ≥25 years old (Huh et al., 2015; 
American College of Obstetricians and Gynecologists, 2016). The rationale for extending 
primary HPV testing to younger women is not clear, but may be indicative of a universal 
screening mentality or a lack of understanding that the HPV infection in teenagers and 
women in their early 20’s often resolves or clears without intervention (Boardman and 
Robison, 2013). Many providers also followed an annual or 2-year screening interval for 
primary HPV testing, despite recommendations for a 3-year interval (Huh et al., 2015; 
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American College of Obstetricians and Gynecologists, 2016) and evidence in other countries 
which supports the effectiveness of even longer intervals, up to 10 years (Peto and Gilham, 
2017; Elfström et al., 2014; Dillner et al., 2008; Gage et al., 2014; Isidean et al., 2016). This 
preference for more frequent screening may reflect a lack of familiarity with screening 
recommendations (Isidean et al., 2016), concerns about maintaining visit volume 
(Henderson et al., 2014) or patient preference (Teoh et al., 2015; Gerend et al., 2017). 
Primary HPV testing of women younger than recommended and screening more frequently 
than recommended will likely result in increased colposcopy referrals (Boardman and 
Robison, 2013) and adverse birth outcomes (Bjørge et al., 2016), with no accompanying rise 
in the detection of high-grade cervical disease.
The strongest predictor of routine recommendation of primary HPV testing in the adjusted 
model was patient HPV vaccination status. Physicians who reported that patient HPV 
vaccination status influenced their cervical cancer screening practices were almost four 
times more likely to routinely recommend primary HPV testing for average-risk, 
asymptomatic women ≥30 years old. It is possible that providers familiar with HPV 
vaccination know that high coverage can result in less HPV infection of vaccine types and 
are aware that future screening can differentiate the most oncogenic types—HPV 16/18, the 
same types in the first generation vaccines—from other types. HPV vaccination has been 
associated with significant decreases in cervical pre-cancers in the US (Benard et al., 2016) 
and the Netherlands (Dijkstra et al., 2016). Similarly, high coverage of the HPV vaccine in 
Australia has resulted in a reduction in HPV 16/18 infections, genital warts, and cervical 
pre-cancers (Brotherton et al., 2016). As a result, Australia has changed from Pap-based 
screening starting at age 18 every 2 years to a strategy of primary HPV testing every 5 years 
starting at age 25 (Australian Government Department of Health, 2017). It should be noted 
that the full impact of HPV vaccination may yet to be fully understood. Specifically, HPV 
vaccination may reduce the positive predictive value of colposcopy (Munro et al., 2017), and 
additional implications of population-based uptake of the vaccine may emerge over time.
In the adjusted model, internists were more likely to recommend primary HPV testing than 
other providers. However, a previous study found that internists were less likely to report 
that primary HPV testing is an effective population-based screening modality than other 
provider groups (Cooper and Saraiya, 2015). It is not clear why internists more often 
recommended primary HPV testing in the present study. In prior research, internists were 
found to be less compliant with cervical cancer screening guidelines than other providers 
(Corbelli et al., 2014). Similarly, internists in the present study more often recommended 
primary HPV testing annually or every 2 years for women of all ages (despite SGO/ASCCP 
interim guidance and ACOG recommendations that primary HPV testing be administered 
every 3 years and reserved for women ≥25 years (Huh et al., 2015; American College of 
Obstetricians and Gynecologists, 2016)). It should also be noted that more than half of 
internists (55.9%) who participated in the 2015 DocStyles survey on which the present study 
was based were excluded from the analyses because they did not perform cervical cancer 
screening. This high rate of opting out of cervical cancer screening among internists is 
consistent with prior research (Cooper and Saraiya, 2014). Thus, internists who perform 
cervical cancer screening should be considered a subset of the US internist population at 
large. In addition, physicians who indicated that practice guidelines did not influence their 
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cervical cancer screening practices were more likely to routinely recommend primary HPV 
testing, which is consistent with the lack of inclusion of this screening option at present in 
the recommendations issued by major organizations (Saslow et al., 2012; US Preventive 
Services Task Force, 2012). Finally, the associations found between routine recommendation 
of primary HPV testing and gender, race, and ethnicity are interesting and need to be 
explored further.
The primary limitation of the present study is its reliance on self-reported data. No 
comparison data for the results reported here were identified, and the use of quota sampling 
(Cumming, 1990) in the present study limits generalizability. However, physicians who 
participated in the 2015 DocStyles surveys were found to be comparable with providers in 
the American Medical Association (AMA) Masterfile® in terms of gender, age, and 
geographic region (Porter Novelli, 2015). It is not known whether providers who responded 
to the survey after sampling quotas were filled or did not respond at all differed from 
providers included in the study. Also, it is important to emphasize that the extent to which 
provider recommendation of primary HPV testing, the focus of this study, translates into 
actual use is not known. Providers were asked about their screening recommendations in a 
hypothetical context, and no validation data from medical record review or other sources 
was available.
Primary HPV testing in the United States may be out of sync with current guidelines. ACS 
and USPSTF have not endorsed primary HPV testing, and the guidance issued by SGO/
ASCCP (Huh et al., 2015) and ACOG (American College of Obstetricians and 
Gynecologists, 2016) limit this screening approach to women ≥25 years old. Yet, four out of 
10 providers reported recommending primary HPV testing to women of all ages. No firm 
consensus on the appropriate screening intervals emerged, but both providers in the current 
study and women (Ogilvie et al., 2013) appear to be less supportive of primary HPV testing 
intervals longer than 3 years. Provider support for annual HPV testing was especially 
troubling. Annual cervical cancer screening is not recommended for women at any age by 
any modality. Given lower test specificity, over-screening with the HPV test is associated 
with greater peril than over-screening with the Pap test (Naber et al., 2016). Increased 
detection of transient HPV infections, particularly in younger women, will augment 
unnecessary diagnostic procedures and follow-up For over-screened women, HPV testing 
(either stand alone or co-testing) may cause more harm than benefit. Increasing providers’ 
and women’s acceptance and adoption of recommended screening intervals is an urgent 
public health objective as HPV testing and vaccination become part of a comprehensive 
prevention strategy.
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Fig. 1. 
Screening interval recommended for primary human papillomavirus (HPV) testing with 
average-risk, asymptomatic women ≥30 years by provider group, DocStyles survey, 2015.
Note: Analyses were limited to physicians who recommended primary HPV screening for 
average-risk asymptomatic women ≥30 years old (145 internists, 144 family practitioners, 
and 55 obstetrician-gynecologists).
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Table 2
Provider characteristics by routine recommendation of primary human papillomavirus (HPV) testing for 
average-risk, asymptomatic women ≥30 years, DocStyles survey, 2015 (N = 843).
Characteristic Responses Primary HPV testing for average-risk, 
asymptomatic women ≥30 years
pa
Does not 
recommend (%)
Recommends (%)
Specialty Internist 38.6 61.4 < 0.001
Family practitioner 60.5 39.5
Obstetrician-gynecologist 77.3 22.7
Gender Male 54.7 45.3 < 0.001
Female 68.1 31.9
Race White 64.7 35.3 < 0.001
Asian 45.5 54.5
Black 83.3 16.7
Other 55.4 44.6
Hispanic ethnicity Yes 41.7 58.3 0.03
No 60.0 40.0
Years in practice < 10 58.4 41.6 0.78
10–19 58.3 41.7
≥20 60.8 39.2
Number of practitioners in practice Solo practitioner 61.2 38.8 0.45
2–4 54.7 45.3
5–9 60.4 39.6
≥10 61.1 38.9
Teaching hospital privileges Yes 58.8 41.2 0.81
No 59.6 40.4
Geographic region Northeast 59.2 40.8 0.67
South 56.5 43.5
Midwest 61.9 38.1
West 60.0 40.0
Financial status of majority of 
patients treated
Poor (< $25,000) 74.5 25.5 0.06
Lower middle ($25,000–$49,999) 64.2 35.8
Middle ($50,000–$99,999) 55.9 44.1
Upper middle ($100,000–$249,999) 55.7 44.3
Affluent (≥$250,000) 58.9 41.1
Number of cervical cancer screenings 
performed during a typical month
1–14 53.8 46.2 0.004
15–44 56.8 43.2
≥45 67.0 33.0
Factors influencing cervical cancer 
screening practicesb
Practice guidelines 60.7 39.3 0.01
Clinical experience 58.8 41.2 0.68
Patient preference influences 52.2 47.8 < 0.001
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Characteristic Responses Primary HPV testing for average-risk, 
asymptomatic women ≥30 years
pa
Does not 
recommend (%)
Recommends (%)
Patient HPV vaccination status 40.7 59.3 < 0.001
Note: Analyses were limited to physicians who reported that cervical cancer screening was within the scope of their practice and performed 
cervical cancer screening during a typical month.
a
Percentages were compared using Pearson Chi-square asymp. two-sided tests.
b
Influences cervical cancer screening practices “somewhat” or “very much.”
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Table 3
Significant predictors of routine recommendation of primary human papillomavirus (HPV) testing for average-
risk, asymptomatic women ≥30 years old among US providers who perform cervical cancer screening, 
multivariate logistic regression, DocStyles survey, 2015 (N = 843).
Significant predictors Predictive category Adj. OR 95% CI Reference category
Specialty Family practitioner 0.44 0.30–0.63 Internist
Obstetrician-gynecologist 0.31 0.18–0.52
Gender Male 1.56 1.11–2.21 Female
Race Asian 1.95 1.36–2.81 White
Black 0.46 0.12–1.80
Other 0.96 0.54–1.70
Hispanic ethnicity Yes 2.38 1.09–5.20 No
Factors influencing cervical 
cancer screening practices
Influenced by patient HPV vaccination 
status
3.96 2.82–5.57 Not influenced by patient HPV 
vaccination status
Influenced by practice guidelines 0.45 0.27–0.74 Not influenced by practice 
guidelines
Note: Table includes variables in the multivariate model with one or more significant categories. The forward, stepwise multivariate model included 
variables significantly associated with routine recommendation of primary HPV testing for average-risk, asymptomatic women in bivariate analyses 
(Table 2): specialty, gender, race, ethnicity, number of cervical cancer screenings performed during a typical month, and three influences on 
cervical cancer screening practices—practice guidelines, patient preference, and patient HPV vaccination status. Analyses were limited to 
physicians who reported that cervical cancer screening was within the scope of their practice and performed cervical cancer screening during a 
typical month.
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